NewEdge Advisors LLC Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• NewEdge Advisors increased its Regeneron stake by 56.5% in the second quarter, holding 11,911 shares valued at approximately $7.4 million. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 and revenue of $4.29 billion, exceeding estimates and representing 16.7% year-over-year revenue growth. Analysts maintain a “Moderate Buy” consensus with an average price target of $802.18.
• Potential risks include a securities class-action lawsuit linked to the failed Fianlimab-Libtayo melanoma trial, while RBC believes patent protection for Eylea HD may be retained, helping defend the company against biosimilar competition.

NewEdge Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,911 shares of the biopharmaceutical company's stock after purchasing an additional 4,301 shares during the quarter. NewEdge Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $7,427,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of REGN. California State Teachers Retirement System grew its position in shares of Regeneron Pharmaceuticals by 63,274.2% in the second quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company's stock valued at $60,934,625,000 after purchasing an additional 97,569,482 shares in the last quarter. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Norges Bank purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 142.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock valued at $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Finally, Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock worth $3,432,488 in the last 90 days. Company insiders own 6.97% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. HSBC boosted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a "buy" rating in a report on Thursday. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $781.49 on Monday. The business has a 50-day moving average price of $754.93 and a 200 day moving average price of $720.12. The stock has a market cap of $80.46 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 1.53 and a beta of 0.20. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the company posted $12.81 earnings per share. The firm's revenue was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.